Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Blood-based Biomarkers for Early Alzheimer's Disease Screening

Authors not listed

Peking University First Hospital · 2024

Abstract

The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are: * to identify core blood biomarker suitable for early screening of AD. * to establish a comprehensive model for the early identification of AD.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Anonymous. (2024). Blood-based Biomarkers for Early Alzheimer's Disease Screening. <em>Peking University First Hospital</em>. https://clinicaltrials.gov/study/NCT06477484
Vancouver
Anonymous. Blood-based Biomarkers for Early Alzheimer's Disease Screening. Peking University First Hospital. 2024.
BibTeX
@misc{anon2024Bloodb, title = {Blood-based Biomarkers for Early Alzheimer's Disease Screening}, author = {Anonymous}, journal = {Peking University First Hospital}, year = {2024}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings